Bengt Gustavsson

MD, Ph.D, Prof. / Director

Bengt is the founder of Isofol Medical and the head of surgical oncology at Sahlgrenska University Hospital, Gothenburg, Sweden. He co-discovered the positive effects of Leucovorin on 5-FU that created the widely used combination treatment against colorectal cancer called 5-FU-LV.

Bengt is also the founder of Carmel Pharma. Since 1996, he is a member of the scientific committee of the Swedish Cancer Society and he has been a member of its scientific committee for two terms. He is a member of the American Society of Clinical Oncology, European Surgical Society, Swedish Surgical Society and the Swedish Society of Colon and Rectal Surgeons.

Position: Director / Board Member

Elected: 2008

Year of birth: 1947

Holdings*:3 454 811 shares

Independent in relation to the company and its management: No

Independent in relation to larger shareholders: No

*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of 1th of March.

About Isofol

Isofol Medical AB (publ) is a biotech company within the field of oncology developing arfolitixorin, primarily as a treatment for advanced colorectal cancer and as a rescue drug after high-dose methotrexate treatment in osteosarcoma (bone cancer).